Company / Current Liabilities
Aclaris Therapeutics, Inc. Current Liabilities History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$28.6M
FY2025
5-year range
$21.9M / $31.6M
FY2021-FY2025
Trend
-9.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Current Liabilities has fluctuated over the past 9 years, ranging from $13M in FY2017 to $32M in FY2024.
Based on SEC 10-K filings.
$29M in FY2025 with a 5-year CAGR of +14.0%.
Improved from $31M to $29M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +9.3%
- 5-Year CAGR
- +14.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +14.0%, indicating consistent growth.
- In FY2025, current liabilities decreased 9.3% year-over-year.
- Peak current liabilities was recorded in FY2024.
- Lowest current liabilities in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -5.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $28.6M | -9.3% |
| FY2024 | $31.6M | +2.1% |
| FY2023 | $31.0M | +41.1% |
| FY2022 | $21.9M | -4.3% |
| FY2021 | $22.9M | +54.2% |
| FY2020 | $14.9M | -33.7% |
| FY2019 | $22.4M | -18.0% |
| FY2018 | $27.3M | +114.2% |
| FY2017 | $12.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026